Search Results

The Alliance for Regenerative Medicine and the National Institute for Innovation in Manufacturing BioPharmaceuticals released Project A-Cell, a multistakeholder collaboration to incorporate Quality by Design principles into a manufacturing case study of a Chimeric Antigen Receptor T-cell therapy.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc.

ACell, Inc., a leading regenerative medicine company, announced today that it has received CE mark approval for its MicroMatrix®, Cytal® Wound Matrix, and Cytal® Burn Matrix devices

ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has launched the roadshow for the initial

Integra LifeSciences Holdings Corporation (NASDAQ:IART) a leading global medical technology company, today announced it has entered into a definitive agreement to acquire ACell, Inc.

ACell, Inc. announced their participation in Arab Health 2019, being held January 28-31 in Dubai. ACell will be part of the State of Maryland Delegation at the USA Partnership Pavilion.

ACell announced that it has received the Supplier Legacy Award from Premier Inc., a leading healthcare improvement company.

ACell, Inc. announced that it has reached final settlement agreements with the United States Attorney’s Office for the District of Maryland and three states to resolve all civil and criminal allegations relating to the sales and marketing of the Company’s products.

3M today announced it has completed the acquisition of Acelity, Inc. and its KCI subsidiaries worldwide from a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of the Canada Pension Plan Investment Board and the Public Sector Pension Investment Board for a total enterprise value of approximately $6.7 billion, including assumption of debt and other adjustments.

ACell, Inc. announced that it has entered into an exclusive distribution agreement with MyungMoon Bio Co. Ltd.